CN101891647A - 一种乌苯美司的制备方法 - Google Patents
一种乌苯美司的制备方法 Download PDFInfo
- Publication number
- CN101891647A CN101891647A CN2010101241327A CN201010124132A CN101891647A CN 101891647 A CN101891647 A CN 101891647A CN 2010101241327 A CN2010101241327 A CN 2010101241327A CN 201010124132 A CN201010124132 A CN 201010124132A CN 101891647 A CN101891647 A CN 101891647A
- Authority
- CN
- China
- Prior art keywords
- ubenimex
- preparation
- compound
- reaction
- edci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 title claims abstract description 60
- 229950009811 ubenimex Drugs 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims abstract description 18
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims abstract description 18
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims abstract description 17
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 15
- 150000001408 amides Chemical class 0.000 claims abstract description 10
- 229960002885 histidine Drugs 0.000 claims abstract description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 7
- 229930064664 L-arginine Natural products 0.000 claims abstract description 7
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 31
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000013078 crystal Substances 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 16
- 235000019441 ethanol Nutrition 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 11
- 239000012046 mixed solvent Substances 0.000 claims description 11
- 238000001953 recrystallisation Methods 0.000 claims description 11
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- 125000003368 amide group Chemical group 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 238000006722 reduction reaction Methods 0.000 claims description 7
- JNJCEALGCZSIGB-UHFFFAOYSA-N 2-hydroxy-4-phenylbutanoic acid Chemical compound OC(=O)C(O)CCC1=CC=CC=C1 JNJCEALGCZSIGB-UHFFFAOYSA-N 0.000 claims description 6
- MBRRYUQWSOODEO-LBPRGKRZSA-N benzyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OCC1=CC=CC=C1 MBRRYUQWSOODEO-LBPRGKRZSA-N 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 229950004288 tosilate Drugs 0.000 claims description 6
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 5
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 5
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- 238000005882 aldol condensation reaction Methods 0.000 claims description 4
- 230000031709 bromination Effects 0.000 claims description 4
- 238000005893 bromination reaction Methods 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
- 238000005576 amination reaction Methods 0.000 claims description 3
- 230000006196 deacetylation Effects 0.000 claims description 3
- 238000003381 deacetylation reaction Methods 0.000 claims description 3
- 238000010511 deprotection reaction Methods 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 claims description 2
- 229940099204 ritalin Drugs 0.000 claims description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 32
- 230000006340 racemization Effects 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
- LDSJMFGYNFIFRK-BDAKNGLRSA-N (2s,3r)-3-azaniumyl-2-hydroxy-4-phenylbutanoate Chemical compound OC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 LDSJMFGYNFIFRK-BDAKNGLRSA-N 0.000 abstract description 3
- 238000009833 condensation Methods 0.000 abstract description 2
- 230000005494 condensation Effects 0.000 abstract description 2
- DQZRIAPQRYKDHC-MNOVXSKESA-N (2s,3r)-3-acetamido-2-hydroxy-4-phenylbutanoic acid Chemical compound CC(=O)N[C@@H]([C@H](O)C(O)=O)CC1=CC=CC=C1 DQZRIAPQRYKDHC-MNOVXSKESA-N 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 abstract 1
- XOALQTLEONZTFZ-UHFFFAOYSA-N OC(C(=O)O)CCC1=CC=CC=C1.C(C)(=O)NC=1C(=C(C=CC1)[As](O)(O)=O)O Chemical compound OC(C(=O)O)CCC1=CC=CC=C1.C(C)(=O)NC=1C(=C(C=CC1)[As](O)(O)=O)O XOALQTLEONZTFZ-UHFFFAOYSA-N 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 239000000047 product Substances 0.000 description 20
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 19
- 229930195722 L-methionine Natural products 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 13
- DFXQLNZIJHDUHB-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(C(C(=O)O)(O)NC=O)CC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC(C(C(=O)O)(O)NC=O)CC1=CC=CC=C1 DFXQLNZIJHDUHB-UHFFFAOYSA-N 0.000 description 12
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000001291 vacuum drying Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000012535 impurity Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- -1 amino compound Chemical class 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- NHNUFAASKXPOQA-UHFFFAOYSA-N (3-acetamido-2-hydroxyphenyl)arsonic acid Chemical compound C(C)(=O)NC=1C(=C(C=CC1)[As](O)(=O)O)O NHNUFAASKXPOQA-UHFFFAOYSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000004395 L-leucine Substances 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229960003136 leucine Drugs 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- LDSJMFGYNFIFRK-UHFFFAOYSA-N 3-azaniumyl-2-hydroxy-4-phenylbutanoate Chemical compound OC(=O)C(O)C(N)CC1=CC=CC=C1 LDSJMFGYNFIFRK-UHFFFAOYSA-N 0.000 description 5
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 5
- 229930182819 D-leucine Natural products 0.000 description 5
- 235000019454 L-leucine Nutrition 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102100032126 Aminopeptidase B Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 3
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 3
- 108090000449 aminopeptidase B Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OWDHNYUHCPSQFR-UHFFFAOYSA-N 2,4-diphenylpentan-3-one Chemical compound C=1C=CC=CC=1C(C)C(=O)C(C)C1=CC=CC=C1 OWDHNYUHCPSQFR-UHFFFAOYSA-N 0.000 description 1
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 101710097665 Leucine aminopeptidase 1 Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- GZERAQPQSAUYIM-UHFFFAOYSA-N NCC(C1=CC=CC=C1)C(=O)C(CN)C1=CC=CC=C1 Chemical compound NCC(C1=CC=CC=C1)C(=O)C(CN)C1=CC=CC=C1 GZERAQPQSAUYIM-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005575 aldol reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- DHHXWJHVYUNCFV-UHFFFAOYSA-N n-[1-(4-phenylphenyl)ethyl]hydroxylamine Chemical class C1=CC(C(NO)C)=CC=C1C1=CC=CC=C1 DHHXWJHVYUNCFV-UHFFFAOYSA-N 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
肽酶 B | 亮氨酸氨基肽酶 | |
1. Ubenimex (2S, 3R, 5L) | 0.05 | 0.01 |
2. Formula 1-b (2R, 3S, 5L) | > 250 | >250 |
3. Formula 1-c (2S, 3R, 5D) | 0.56 | 3.40 |
4. Formula 1-d (2R, 3S, 5D) | 135 | >250 |
批号 | 0701 | 0702 | 0703 | 0704 | 0705 |
ee% | 89.84% | 94.98% | 96.00% | 98.98% | 99.50% |
[α] ° | 26.6 ° | 27.5 ° | 28.3 ° | 28.4 ° | 28.4 ° |
批号 | 0901 | 0902 | 0903 | 0904 | 0905 |
ee% | 99.68% | 99.78% | 99.80% | 99.88% | 99.90% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010124132 CN101891647B (zh) | 2010-03-15 | 2010-03-15 | 一种乌苯美司的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010124132 CN101891647B (zh) | 2010-03-15 | 2010-03-15 | 一种乌苯美司的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101891647A true CN101891647A (zh) | 2010-11-24 |
CN101891647B CN101891647B (zh) | 2012-12-19 |
Family
ID=43101024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010124132 Active CN101891647B (zh) | 2010-03-15 | 2010-03-15 | 一种乌苯美司的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101891647B (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102491915A (zh) * | 2011-12-02 | 2012-06-13 | 深圳万乐药业有限公司 | 一种乌苯美司水解中间体的制备方法 |
CN103058900A (zh) * | 2012-12-14 | 2013-04-24 | 重庆康乐制药有限公司 | 一种r-二苯甲基亚硫酰乙酸的制备方法 |
CN103333089A (zh) * | 2013-06-20 | 2013-10-02 | 深圳万乐药业有限公司 | N-[(2s,3r)-4-苯基-3-苄基-3-苄氧甲酰氨基-2-羟基丁酰]-l-亮氨酸苄酯的晶型及其制备方法 |
CN103360277A (zh) * | 2013-04-01 | 2013-10-23 | 上海信谊万象药业股份有限公司 | 一种乌苯美司重结晶的方法 |
CN104341317A (zh) * | 2014-10-28 | 2015-02-11 | 苏州摩尔医药有限公司 | 一种不对称合成乌苯美司的方法 |
CN104447394A (zh) * | 2014-12-17 | 2015-03-25 | 成都傲飞生物化学品有限责任公司 | 一种乌苯美司的新型合成工艺 |
CN104496843A (zh) * | 2014-12-08 | 2015-04-08 | 山东益康药业股份有限公司 | 一种乌苯美司的合成方法 |
CN105646273A (zh) * | 2014-08-21 | 2016-06-08 | 江苏吴中苏药医药开发有限责任公司 | 一种乌苯美司的合成方法 |
CN105968026A (zh) * | 2016-08-01 | 2016-09-28 | 四川青木制药有限公司 | 一种高纯度乌苯美司的制备方法 |
CN106631880A (zh) * | 2016-08-01 | 2017-05-10 | 四川青木制药有限公司 | 一种乌苯美司δ晶型及其制备方法 |
CN109721505A (zh) * | 2018-12-26 | 2019-05-07 | 深圳万乐药业有限公司 | 一种乌苯美司合成中的杂质及其制备方法 |
CN113563221A (zh) * | 2018-07-09 | 2021-10-29 | 成都苑东生物制药股份有限公司 | 一种乌苯美司γ晶型的制备方法 |
CN115594606A (zh) * | 2022-12-16 | 2023-01-13 | 成都傲科新技术有限责任公司(Cn) | 苏式-2-羟基-3-乙酰氨基-4-苯基羰基丁酸不对称合成方法 |
CN115784918A (zh) * | 2022-11-24 | 2023-03-14 | 四川青木制药有限公司 | 一种高纯度乌苯美司中间体的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4453003A (en) * | 1978-11-25 | 1984-06-05 | Hamao Umezawa | Process for producing threo-3-amino-2-hydroxy-butanoyl-aminoacetic acids as well as novel intermediates therefor and process for producing them |
JPS61178955A (ja) * | 1985-12-02 | 1986-08-11 | Nippon Kayaku Co Ltd | スレオ−3−アミノ−2−ヒドロキシ−4−フエニル酪酸の製造法 |
-
2010
- 2010-03-15 CN CN 201010124132 patent/CN101891647B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4453003A (en) * | 1978-11-25 | 1984-06-05 | Hamao Umezawa | Process for producing threo-3-amino-2-hydroxy-butanoyl-aminoacetic acids as well as novel intermediates therefor and process for producing them |
JPS61178955A (ja) * | 1985-12-02 | 1986-08-11 | Nippon Kayaku Co Ltd | スレオ−3−アミノ−2−ヒドロキシ−4−フエニル酪酸の製造法 |
Non-Patent Citations (2)
Title |
---|
BRYAN H NORMAN, ET AL: "A Stereospecific Synthesis of (-)-Bestatin from L-Malic acid", 《TETRAHEDRON LETTERS》 * |
RINZO NISHIZAWA, ET AL: "A FACILE SYNTHESIS OF ANTIBIOTICS", 《THE JOURNAL OF ANTIBIOTICS》 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102491915A (zh) * | 2011-12-02 | 2012-06-13 | 深圳万乐药业有限公司 | 一种乌苯美司水解中间体的制备方法 |
CN102491915B (zh) * | 2011-12-02 | 2013-08-28 | 深圳万乐药业有限公司 | 一种乌苯美司水解中间体的制备方法 |
CN103058900A (zh) * | 2012-12-14 | 2013-04-24 | 重庆康乐制药有限公司 | 一种r-二苯甲基亚硫酰乙酸的制备方法 |
CN103058900B (zh) * | 2012-12-14 | 2014-11-26 | 重庆康乐制药有限公司 | 一种r-二苯甲基亚硫酰乙酸的制备方法 |
CN103360277A (zh) * | 2013-04-01 | 2013-10-23 | 上海信谊万象药业股份有限公司 | 一种乌苯美司重结晶的方法 |
CN103333089A (zh) * | 2013-06-20 | 2013-10-02 | 深圳万乐药业有限公司 | N-[(2s,3r)-4-苯基-3-苄基-3-苄氧甲酰氨基-2-羟基丁酰]-l-亮氨酸苄酯的晶型及其制备方法 |
CN105646273A (zh) * | 2014-08-21 | 2016-06-08 | 江苏吴中苏药医药开发有限责任公司 | 一种乌苯美司的合成方法 |
CN105646273B (zh) * | 2014-08-21 | 2017-12-19 | 江苏吴中苏药医药开发有限责任公司 | 一种乌苯美司的合成方法 |
CN104341317B (zh) * | 2014-10-28 | 2016-05-11 | 苏州摩尔医药有限公司 | 一种不对称合成乌苯美司的方法 |
CN104341317A (zh) * | 2014-10-28 | 2015-02-11 | 苏州摩尔医药有限公司 | 一种不对称合成乌苯美司的方法 |
CN104496843A (zh) * | 2014-12-08 | 2015-04-08 | 山东益康药业股份有限公司 | 一种乌苯美司的合成方法 |
CN104496843B (zh) * | 2014-12-08 | 2017-02-22 | 山东益康药业股份有限公司 | 一种乌苯美司的合成方法 |
CN104447394A (zh) * | 2014-12-17 | 2015-03-25 | 成都傲飞生物化学品有限责任公司 | 一种乌苯美司的新型合成工艺 |
CN106631880A (zh) * | 2016-08-01 | 2017-05-10 | 四川青木制药有限公司 | 一种乌苯美司δ晶型及其制备方法 |
CN105968026B (zh) * | 2016-08-01 | 2017-06-16 | 四川青木制药有限公司 | 一种高纯度乌苯美司的制备方法 |
CN105968026A (zh) * | 2016-08-01 | 2016-09-28 | 四川青木制药有限公司 | 一种高纯度乌苯美司的制备方法 |
CN106631880B (zh) * | 2016-08-01 | 2018-06-01 | 四川青木制药有限公司 | 一种乌苯美司δ晶型及其制备方法 |
CN113563221A (zh) * | 2018-07-09 | 2021-10-29 | 成都苑东生物制药股份有限公司 | 一种乌苯美司γ晶型的制备方法 |
CN109721505A (zh) * | 2018-12-26 | 2019-05-07 | 深圳万乐药业有限公司 | 一种乌苯美司合成中的杂质及其制备方法 |
CN115784918A (zh) * | 2022-11-24 | 2023-03-14 | 四川青木制药有限公司 | 一种高纯度乌苯美司中间体的制备方法 |
CN115594606A (zh) * | 2022-12-16 | 2023-01-13 | 成都傲科新技术有限责任公司(Cn) | 苏式-2-羟基-3-乙酰氨基-4-苯基羰基丁酸不对称合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101891647B (zh) | 2012-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101891647B (zh) | 一种乌苯美司的制备方法 | |
CN112384519B (zh) | 一种肽硼酸酯类化合物的合成与用途 | |
CN102985416A (zh) | 制备凝血酶特异性抑制剂的方法 | |
CN105884781A (zh) | 一种枸橼酸托法替布的制备方法 | |
CN103539795A (zh) | 阿哌沙班的多晶型及其制备方法 | |
CN105061506B (zh) | 抗肿瘤药物ap26113的制备方法 | |
CN104987355A (zh) | 一种索非布韦的中间体化合物的合成方法 | |
CN106117148A (zh) | 一种洛匹那韦的制备和纯化工艺 | |
CN112110897B (zh) | 一种氘代克里唑蒂尼及其衍生物的制备方法 | |
CN103304629A (zh) | 一种高光学纯度硼替佐米的制备方法及其中间体 | |
CN104356012A (zh) | 盐酸沙格雷酯光降解杂质的制备方法 | |
CN104356205A (zh) | 一种卡非佐米的纯化方法 | |
CN104402973A (zh) | 一种卡非佐米无定型晶的制备方法 | |
CN103864889A (zh) | 环氧酮化合物、其制备方法及卡非佐米的制备方法 | |
CN101735220B (zh) | 一种6,7-二氢-6-巯基-5H-吡唑[1,2-a][1,2,4]三唑内鎓氯化物的晶型及其制备方法 | |
WO2022017317A1 (zh) | 一种规模化合成河豚毒素的方法 | |
WO2018113277A1 (zh) | 一种雷迪帕韦的制备方法及制备雷迪帕韦的中间体 | |
CN103420999A (zh) | 一种适合工业化生产达沙替尼的合成方法 | |
CN114262359A (zh) | 一种卡非佐米杂质的制备方法 | |
CN113501853A (zh) | 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途 | |
CN105294479A (zh) | 一种3r-氨基取代丁酰胺衍生物的制备方法 | |
CN102260255B (zh) | 一种9,10-二甲氧基-1,3,4,6,7,11b-六氢-3-异丁基-2H-苯并[a]喹嗪-2-酮的简便合成方法 | |
JP2020070296A (ja) | リナグリプチンの製造法 | |
CN101289426B (zh) | 一种制备利什曼原虫病抑制剂的方法 | |
CN103421033B (zh) | 一种制备(1r)-(s)-蒎烷二醇-1-氨基-3-甲基丁烷-1-硼酸酯及其盐的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200701 Address after: No.333, Jiangnan Road, Hengdian, Dongyang City, Jinhua City, Zhejiang Province Co-patentee after: APELOA PHARMACEUTICAL Co.,Ltd. Patentee after: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. Address before: 322118, 333 Jiangnan Road, Dongyang, Zhejiang, Jinhua, Hengdian Patentee before: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of ubenimex Effective date of registration: 20210922 Granted publication date: 20121219 Pledgee: Dongyang sub branch of Bank of China Ltd. Pledgor: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2021330001745 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230925 Granted publication date: 20121219 Pledgee: Dongyang sub branch of Bank of China Ltd. Pledgor: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2021330001745 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Preparation Method of Ubenamex Effective date of registration: 20231007 Granted publication date: 20121219 Pledgee: Dongyang sub branch of Bank of China Ltd. Pledgor: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980059587 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |